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Associations between metabolic disorders
and risk of cancer in Danish men and
women – a nationwide cohort study
Siv Mari Berger1*, Gunnar Gislason1,5,6, Lynn L. Moore3, Charlotte Andersson1, Christian Torp-Pedersen2,
Gerald V. Denis3,4 and Michelle Dalgas Schmiegelow1
Abstract
Background: The prevalence of metabolic disorders is increasing and has been suggested to increase cancer risk, but
the relation between metabolic disorders and risk of cancer is unclear, especially in young adults. We investigated the
associations between diabetes, hypertension, and hypercholesterolemia on risk of all-site as well as site-specific cancers.
Methods: We consecutively included men and women from nationwide Danish registries 1996–2011, if age 20–89
and without cancer prior to date of entry. We followed them throughout 2012. Metabolic disorders were defined
using discharge diagnosis codes and claimed prescriptions. We used time-dependent sex-stratified Poisson regression
models adjusted for age and calendar year to assess associations between metabolic disorders, and risk of all-site and
site-specific cancer (no metabolic disorders as reference).
Results: Over a mean follow-up of 12.6 (±5.7 standard deviations [SD]) years, 4,826,142 individuals (50.2 % women)
with a mean age of 41.4 (±18.9 SD) years had 423,942 incident cancers. Incidence rate ratios (IRRs) of all-site cancer in
patients with diabetes or hypertension were highest immediately following diagnosis of metabolic disorder. In women,
cancer risk associated with diabetes continued to decline albeit remained significant (IRRs of 1.18–1.22 in years 1–8
following diagnosis). For diabetes in men, and hypertension, IRRs stabilized and remained significantly increased after
about one year with IRRs of 1.10-1.13 in men for diabetes, and 1.07–1.14 for hypertension in both sexes. Conversely,
no association was observed between hypercholesterolemia (treatment with statins) and cancer risk. The association
between hypertension and cancer risk was strongest in young adults aged 20–34 and decreased with advancing age.
Conclusions: Diabetes and hypertension were associated with increased risk of all-site cancer.
Keywords: Cancer, Metabolic, Diabetes, Hypertension, Hypercholesterolemia, Epidemiology
Background
Cancer is among the leading causes of death across all
age groups in the western world [1], and as the only
European country, cancer is now the leading cause of
death in Denmark in both men and women [2]. In paral-
lel to the rising clinical, social and economic burdens of
cancer [3, 4], the prevalences of associated metabolic
disorders such as diabetes, hypertension and hyperchol-
esterolemia are rapidly increasing [5], and the studies of
the relation between metabolic disorders and cancer risk
are conflicting. Overweight and obesity have been linked
with excess cancer risk in numerous studies [6–8],
although it may be, as with cardiovascular disease [9],
that the metabolic disorders associated with obesity
are stronger predictors of cancer risk than obesity it-
self [10, 11]. Greater attention has been paid to the pos-
sible linkage between metabolic disorders and cancer risk
in recent years [12–14], but many smaller studies were
limited by insufficient statistical power to study the associ-
ations between individual metabolic disorders and cancer
risk across sex and the life span of adult life, especially for
cancer subtypes. Although meta-analyses and large studies
exist within the literature, with the metabolic syndrome
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and cancer (Me-Can) project as one of the largest with
over 500,000 participants, large-scale studies investigating
the associations between metabolic disorders, and risk of
all-site cancer as well as site-specific cancers, are still
sparse, and the association largely unaccounted for in
young adults.
This nationwide cohort study aimed to investigate the
associations between metabolic disorders, namely diabetes,
hypertension and hypercholesterolemia, and risk of cancer
(all sites) as well as selected cancer subtypes in men and
women aged 20–89 years over 17 years of follow-up.
Methods
Data sources
In Denmark, the health care system is governmentally
financed, and for administrative purposes the Danish
government keeps comprehensive and nationwide regis-
ters on several health care and population related vari-
ables. Each resident is given a unique and permanent
identification number; therefore, cross-linkage of the dif-
ferent national registries at an individual level is possible.
For this study, we cross-linked data from four different
registers. The National Population Register includes in-
formation on vital status, date of birth, and immigra-
tion/emigration. The Danish National Patient Register
(DNPR) holds information on all hospitalizations since
1977, including dates and discharge diagnoses according
to the International Classification of Diseases (ICD);
ICD-8 was used until 1993 and ICD-10 from 1994 on-
wards. The Danish Register of Causes of Death holds in-
formation on diagnoses related to the cause of death.
Finally, the Danish Register of Medicinal Product Statis-
tics (National Prescription Register) keeps records of all
prescriptions dispensed from Danish pharmacies since
1995; all drugs are coded according to the Anatomical
Therapeutic Chemical (ATC) classification system, and the
register has been found to be accurate [15].
Study population
The study population of interest consisted of all Danish
residents, included consecutively during January 1, 1996
through December 31, 2011. Each individual was in-
cluded in the study population at the last of the follow-
ing events: on January 1 1996, the date the individual
turned 20 years old or the date of immigration to
Denmark. The population was followed from date of
entry until first cancer event, emigration, death, date of
90th birthday or December 31, 2012, whichever oc-
curred first. We excluded individuals with a history of
cancer (ICD-8 codes starting with numbers 140–209,
ICD-10 codes C) prior to date of entry.
Non-melanoma skin cancer was not included in the
definition of cancer (ICD-8 code 173, ICD-10 code C44),
as these common and generally non-fatal cancers are
most often diagnosed and treated by general practi-
tioners, from whom data are not included in the Danish
registers.
Outcomes
Our primary outcome was first occurrence of any incident
cancer (ICD-10 codes C). Our secondary outcomes were
specific cancer types: breast (ICD-10 code C50), ovarian
(ICD-10 code C56), endometrial (ICD-10 codes C54, C55),
cervical (ICD-10 code C53), kidney (ICD-10 code C64),
lower urinary tract (LUT; ICD-10 codes C66–C68),
pancreatic, (ICD-10 code C25), hepatic (ICD-10 code
C22), gall bladder (ICD-10 code C23), colorectal
(ICD-10 code C18–C20), prostate (ICD-10 code C61),
esophageal (ICD-10 code C15), and lung cancer (ICD-
10 code C33, C34). In this study, we identified cancer
events from the DNPR and the Danish Register of
Causes of Death. A recent validation study reported
that ICD-10 codes of cancer registered in the DNPR
have a positive predictive value of 98.0 − 100 % [16].
Definitions
The metabolic disorders of interest, diabetes, hyperten-
sion and hypercholesterolemia, were defined using ICD
codes and claimed prescriptions from nationwide regis-
ters. Diabetes was defined as diabetes requiring glucose-
lowering medication. Since statin is the drug of choice
when initiating treatment of uncomplicated hypercholes-
terolemia or prophylactic in e.g. cardiovascular disorders
or diabetes, we defined hypercholesterolemia as two
claimed prescriptions for statins. In contrast, other lipid-
lowering drugs, e.g. fibrates, as the first drug are more
likely prescribed to patients with severe hypertri-
glyceridemia. Diabetes and hypercholesterolemia were
thus defined as claiming two prescriptions of glucose-
lowering medication (ATC code A10), and statins (ATC
code C10AA) respectively (date of diagnosis as date of
the second claimed prescription). Hypertension was de-
fined as either 1) a diagnosis of hypertension (ICD-10
codes I10-I15) followed by a subsequent prescription
claim for an antihypertensive drug within 90 days, or 2)
as claimed prescriptions for two different classes of anti-
hypertensive drugs, as described in details previously
[17] (Additional file 1). We defined prevalent diabetes
and hypercholesterolemia as fulfilling the definition for
the respective disorder prior to study entry.
Statistics
All metabolic disorders were modelled as time-dependent
exposure variables. Each individual contributed with
disease-free exposure time until date of diagnosis of a dis-
order, and from this day onwards with time exposed for
the disorder. The lexis-macro was used for all analyses
and several time-scales were used, i.e. calendar year (bands
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were split in 1-year intervals since January 1, 1996), and
duration of each metabolic disorder (bands were split at
the defined date of diagnosis and 3, 6, 9, 12, 18, 24 months
and every third year hereafter). Dichotomous variables
were then created for each metabolic disorder (e.g.
diabetes first 3 months yes/no using the left end point as
reference). Age was calculated at the beginning of each
interval and rounded in 2-year age intervals. In all
analyses, being without the metabolic disorder of interest
was used as reference (e.g. diabetes in month 9–12 was
compared with no diabetes).
Associations between metabolic disorders and cancer
were assessed using multivariable Poisson regression
models with the different metabolic disorders (diabetes,
hypertension and hypercholesterolemia) included in the
same model. We conducted predefined interaction ana-
lyses, specifically assessed interaction between each
metabolic disorder, and age, calendar year, sex and dur-
ation of the metabolic disorder with all interaction
analyses included in the same model. We assessed the
cancer risk stratified by four pre-defined age-categories,
i.e. 20– < 35, 35– < 50, 50– < 65 and ≥65 years.
All statistical calculations were performed using SAS,
version 9.4® (SAS Institute Inc, Cary, NC).
Other analyses
Metformin is sometimes prescribed to women of fertile
age due to polycystic ovary syndrome. We therefore con-
ducted a sensitivity analysis in which we excluded all
prescriptions of metformin (ATC-code A10BA; metfor-
min is the only available biguanid in Denmark) to
women between 20 and 39 years of age [18].
Data on life style habits are not available in the admin-
istrative registries, but are correlated with socioeco-
nomic status [19]. We therefore explored confounding
by socioeconomic status in an analysis stratified by sex
and adjusted for age, calendar year and “highest attained
educational level” at study entry. Immigrants were ex-
cluded from the population for this sensitivity analysis,
because educational level attained abroad is not regis-
tered in Danish registers.
Ethics
In Denmark, no ethics approval is needed for retrospect-
ive register-based studies. This study was approved by
the Danish Data Protection Agency (j.nr.: 2007-58-0015/
GEH-2014016 I-Suite nr: 02734).
Results
From the population register we identified 5,324,572
men and women aged 20–89 years during 1996–2011,
and excluded non-resident individuals (n = 369,400), in-
dividuals with a history of cancer prior to date of entry
(n = 129,028), and misregistered cancers (n = 2). The
final study population consisted of 4,826,142 (49.8 %
men and 50.2 % women). Over a mean follow-up of 12.6
years, there were a total of 423,942 incident cancers, cor-
responding to 30,708,457 person-years (n cancers =
216,806) for women and 30,282,029 person-years (n
cancers = 207,136) for men (Table 1). Presence of
metabolic disorders was rare in both women and
men at study entry (Additional file 1: Table S1). At
the end of follow-up, the total numbers of individ-
uals with the disorder either at date of entry or de-
veloped during follow-up, were for diabetes 6.7 % of
men and 5.6 % of women, for hypertension 22.0 %
of men and 24.6 % of women, and for hypercholes-
terolemia 15.1 % of men and 13.6 % of women. Since
risk of cancer varied according to time elapsed since diag-
nosis (P for all interactions < 0.001), cancer risk was
assessed according to duration of the specific metabolic
disorder. Additionally, due to significant interaction be-
tween hypertension and sex (P for interaction <0.001) and
dyslipidemia and sex (P for interaction < 0.001), albeit not
between diabetes and sex (P for interaction = 0.39), we
stratified all analyses by sex.
We observed that diabetes (Fig. 1) and hypertension
(Fig. 2) were associated with increased risk of cancer
throughout follow-up, whereas hypercholesterolemia
(Fig. 3) over follow-up was associated with decreased or
not significantly associated with cancer risk (IRRs and in-
cidence rates illustrated in Additional file 1: Figure S1).
Risk of being diagnosed with cancer was highest immedi-
ately after diagnosis of diabetes or hypertension, but stabi-
lized after about one year of follow-up. Diabetes appeared
to be associated with the highest relative risks of cancer.
The effect of diabetes and hypertension on cancer risk
differed by age (P for interaction <0.001). The age-
stratified analyses showed that the highest relative risks
of cancer for both men and women were observed in
the younger age groups (Fig. 4a-f ).
In women, diabetes was associated with increased risk
of kidney and hepatic cancer, and strongly associated
with endometrial and pancreatic cancer risk (Additional
file 1: Figure S2A), whereas hypertension in women was
associated with increased risk of kidney and hepatic can-
cer, and we observed a trend of increased risk of gall
bladder cancer (Additional file 1: Figure S2C). In men,
diabetes as well as hypertension was associated with in-
creased risk of hepatic, kidney and colorectal cancer
(Additional file 1: Figure S2B, D), and as in women, dia-
betes was associated with particularly high risk of pancre-
atic cancer (Additional file 1: Figure S2B). Additionally,
hypertension in men was associated with increased risk of
prostate cancer (Additional file 1: Figure S2D). Hyperchol-
esterolemia was not associated with subtypes of cancer in
women (Additional file 1: Figure S2E) or men (Additional
file 1: Figure S2F).
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Other analyses
In sensitivity analysis where we disregarded all prescrip-
tions for metformin to women between 20 and 39 years
old, although attenuated, cancer risk remained signifi-
cantly increased throughout follow-up with the IRR in
women with diabetes stabilizing around 1.15 after one
year of follow-up (results not shown).
Adjustment for educational level did not attenuate
the associations between metabolic disorders and can-
cer (n = 4,223,006 with n = 408,353 cancer events),
and the variable was not retained in the final models.
Due to significant interaction between metabolic
disorders and calendar year, we conducted a sensitiv-
ity analysis stratified by calendar year intervals
Table 1 Exposure time in person years for selected conditions and their combinations in a population of 4,826,142 individuals
Condition Women (N cancer) Men (N cancer)
Sex 30,708,457.18 (216,806) 30,282,029.28 (207,136)
Age
20– < 30 years old 4,623,447.19 (2,408) 4,889,888.43 (2,353)
30– < 40 years old 5,623,447.19 (7,375) 5,942,332.42 (4,645)
40– < 50 years old 5,710,818.95 (18,630) 5,971,215.73 (9,673)
50– < 60 years old 5,450,322.94 (38,244) 5,605,080.44 (28,144)
60– < 70 years old 4,376,820.30 (54,142) 4,304,818.56 (58,945)
70– < 80 years old 3,037,453.17 (53,463) 2,505,2267.45 (65,383)
≥80 years old 1,886,302.14 (42,544) 1,063,426.27 (37,993)
Metabolic disorder
None 25,315,272.16 (140,232) 25,547,307.25 (126,335)
Diabetes only 332,728.06 (3,454) 380,158.52 (4,785)
Hypertension only 2,992,067.24 (42,711) 2,039,554.10 (36,922)
Hypercholesterolemia only 571,379.62 (6,742) 633,138.95 (7,949)
Diabetes and hypertension 200,656.41 (3,509) 214,462.59 (4,495)
Diabetes and hypercholesterolemia 93,514.99 (1,158) 135,247.58 (1,614)
Hypertension and hypercholesterolemia 929,262.47 (14,361) 985,342.21 (18,460)
Diabetes, hypertension and hypercholesterolemia 273,576.23 (4,639) 346,818.08 (6,576)
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Fig. 1 Rate ratios of cancer according to duration of diabetes. Incidence rate ratios of all-site cancer risk according to duration of diabetes, adjusted for
age and calendar year and stratified by sex
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(Additional file 1: Table S2). For diabetes, we found
a tendency towards decreased risk over the calendar
year periods in men, but not in women, however; the
CIs were overlapping in both sexes. For hypertension
and hypercholesterolemia, there were largely un-
altered risks and overlapping CIs over time in both
sexes.
Discussion
The key message of this paper was that being diagnosed
with diabetes and hypertension was associated with in-
creased risk of being diagnosed with cancer, whereas
hypercholesterolemia (defined as treatment with statins)
over the course of follow-up was associated with de-
creased or neutral cancer risk. The relative risk of cancer
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Fig. 3 Rate ratios of cancer according to duration of hypercholesterolemia. Incidence rate ratios of all-site cancer risk according to duration of
hypercholesterolemia, adjusted for age and calendar year and stratified by sex
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Fig. 4 Rate ratios of cancer in women and men according to duration of disorder, stratified by age groups. Incidence rate ratios of all-site cancer
according to duration of a diabetes in women, b diabetes in men, c hypertension in women, d hypertension in men, e hypercholesterolemia in
women and f hypercholesterolemia in men adjusted for age and calendar year, and stratified by age groups. CI, confidence interval
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was particularly high among young adults with meta-
bolic dysfunction and this risk declined steadily with
higher age. Given the observational nature of the data, it
is not possible to study causality.
However, the associations could be caused by 1) re-
verse causality due to undiagnosed cancer prior to
diagnosis of a metabolic disorder; 2) the metabolic
disorder itself increasing the risk of cancer; 3) the risk
factors increasing the risk of developing a metabolic
disorder also increase the risk of cancers, thus con-
founding by unmeasured risk factors most importantly
life style factors; or 4) simply being in contact with
the health care system increases the risk of a cancer
being identified.
Our results showing elevated cancer risk associated
with diabetes are consistent with earlier findings
[20–23], and our findings were of the same magni-
tude of previous findings [12, 23]. A Swedish cohort
study from 1991 observed that over 20 years of
follow-up, diabetes was associated with an increased
cancer risk in women with RR 1.1 (95 % CI = 1.0-
1.1), but not in men, as well as elevated risks of sev-
eral cancer types, including pancreatic, primary liver
and endometrial cancer [23]. This is also in accord-
ance with our findings with the relative risk of endo-
metrial cancer being particularly high in women <50
years old compared with women >50 years old (IRR
for >1.5 years duration of diabetes was 3.94 [95 % CI
2.33-6.70] and 1.81 [95 % CI 1.64-2.00], respectively).
More recently, a study from the Me-Can project of
six cohorts from Norway, Sweden and Austria re-
ported a cancer risk per 1 mmol/L increment of glu-
cose of 1.05 (95 % CI = 1.01-1.10) in men and 1.11
(95 % CI = 1.05-1.16) in women, for incident all-site
cancer [12]. There are several proposed mechanisms
underlying the association between diabetes and can-
cer [24], but increasing evidence points to hyperinsu-
linemia [25], hyperglycemia [26], obesity, and chronic
low-grade inflammation [27–30]. In this context,
obesity is of particular importance, because adipose
tissue is an endocrine organ known to produce sev-
eral adipokines that modulate inflammation and insu-
lin resistance [27, 28]. Approximately 47 % of Danish
residents over 16 years of age are overweight and 13 % are
obese [31, 32], and since about 80 % of patients with type
2 diabetes are overweight or obese [33], a substantial
number of individuals with diabetes in our study can be
assumed to be obese. Obesity is a pro-inflammatory state,
and although the association between hyperglycemia and
overall cancer incidence has been observed to remain after
adjustment for BMI [12], and obesity and hyperglycemia
increased cancer risk synergistically in the Framingham
cohort [11], the causal relation is complex and not fully
understood.
We observed hypertension to be associated with sig-
nificantly increased cancer risks, and although previous
studies on the association between hypertension and
cancer risk are sparse, our finding of a stronger associ-
ation in men was in accordance with an observational
cohort study based on health examinations comprising
nearly 580,000 adults. The study found elevated systolic
blood pressure to be associated with an increase in risk
of total incident cancer among men (hazard ratio 1.17
[95 % CI = 1.10-1.23] in men, but a non-statistically sig-
nificant 6 % increase [95 % CI 0.99-1.14] in women) [13].
We observed that the risk of being diagnosed with a
cancer diagnosis was significantly higher following initi-
ation of medical treatment for a metabolic disorder, which
we interpret as a situation of surveillance bias, as individ-
uals with a known metabolic disorder may have more fre-
quent contact with health professionals and thereby a
higher likelihood of having other metabolic disorders or
preclinical cancers detected. However, even in the long-
term we found diabetes and hypertension to be associated
with increased cancer risk. These findings are in line with
previous studies [34–37], including a Danish study explor-
ing cancer risk according to time elapsed since treatment
initiation with specific types of glucose-lowering medica-
tions [38]. However, since cancer (overt or occult) is dia-
betogenic, part of the association between diabetes and
cancer could be reverse causality as i.e. circulating cyto-
kines in cancer may affect glucose metabolism directly.
Furthermore, both cancer and diabetes can stay subclin-
ical for years, making it a case of the chicken and the egg.
In this study, hypercholesterolemia defined as initi-
ation of treatment with statins, was associated with
decreased or neutral cancer risk in both men and
women. Statins are by far the most commonly used
group of lipid medications, prescribed for elevated total-
cholesterol and LDL-cholesterol, and their use has been
associated with reduced risk of incident cancer in
several, but not all, studies [39–41].
The absolute cancer incidence in young individuals were
low, albeit far from nonexisting, and 4.1 % (n = 16,755) of
the cancer events in this study were detected in indi-
viduals <40 years of age (3.7 % when excluding cervix
cancers). Previous studies on associations between
diabetes, hypertension and hypercholesterolemia, and
overall as well as site-specific cancer, are limited, and
given the low absolute cancer incidence rate, a large-
scale study is needed to conduct reliable analyses. The
most prevalent cancer types also differ between youn-
ger and older age-groups [42]. Young adults diagnosed
with cancer thus constitute a selected population with a
high risk factor burden. In light of the growing obesity
problem worldwide, which also influences the risk of
diabetes, hypertension and hypercholesterolemia, it is
important to be aware of any associations, since
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acknowledgement hereof may increase the likelihood of
early cancer detection.
Strengths and limitations
The major strengths of this nationwide register-based
study are the completeness of the records of hospital diag-
noses and prescription claims; the minimal risk of selec-
tion bias and loss to follow-up; and the large population of
both men and women, which provide sufficient power to
conduct detailed analyses even in low-risk subgroups.
Nonetheless, our study has some important limitations,
primarily that the definition of metabolic disorders pri-
marily relied on claimed prescriptions, and the true num-
ber of people diagnosed with these metabolic disorders
may therefore be underestimated [43]. This study focused
on diabetes requiring treatment with a glucose-lowering
drug. During the later part of the study period it was very
uncommon to use diet alone and therefore we consider
this definition adequate to identify the vast majority of pa-
tients with diabetes, and according to a study by Carsten-
sen et al. identification of diabetes patients by glucose-
lowering drugs in the Danish registries have a sensitivity
of 72 %, and a positive predictive value of 95 % [18]. There
is a risk of overdiagnosing patients with polycystic ovary
syndrome, but we consider this problem minor. In a
recent study a total of 19,195 cases were identified in
Denmark between 1995 and 2012 of which only 10 % re-
ceived metformin [44]. Further, this condition is known to
be associated with an increased risk of diabetes and insulin
resistance. We also conducted a sensitivity analysis ex-
cluding females given metformin between the ages of 20
and 39, which yielded similar results. We did not exclude
gestational diabetes requiring insulin, since these women
have a high risk of later developing diabetes. Lastly for dia-
betes, the vast majority of individuals with diabetes have
type 2 diabetes, which is often treated with metformin ini-
tially; a drug linked to decreased cancer incidence in re-
cent years [24], and our findings may therefore be an
underestimation of the true risk.
For hypertension, 23.3 % of our study population was
defined as having hypertension either at study entry or de-
veloped during follow-up, which is comparable to the age-
adjusted prevalence of 22.3 % found by a comprehensive
clinical study of Danish adults aged 20-89 [45]. Angioten-
sin receptor blockers and angiotensin converting enzyme
inhibitors are two of the most commonly used antihyper-
tensive agents. Although study findings are conflicting re-
garding their relation to cancer risk [46-49], the majority
of studies conclude that antihypertensive agents do not
initiate cancer development [37, 47, 50], and recent stud-
ies even suggest a possible inverse association with cancer
incidence [48, 51].
Cancer events were primarily identified from DNPR
with supplement from the Danish Register of Causes of
Death. We did not have access to The Danish Cancer
Registry, which primarily gathers information from
DNPR, in addition to the Danish Register of Causes of
Death, and finally, from the Danish Pathology Registry.
Since we do not have access to the pathology registry,
our study may underestimate the number of cancer inci-
dences, although the number is considered low, since
the Danish Pathology Registry forward information to
the Danish Register of Causes of Death.
Data on anthropometric measures, life style habits and
smoking are unfortunately not available from the Danish
nationwide registers. Presence of metabolic disorders
may be a marker of obesity, poor diet, physical inactivity
and smoking, all of which are known to increase the risk
of cancer, i.e. smoking strongly increases the risk of sev-
eral cancers, particularly lung cancer and cancer of the
urinary bladder. Socioeconomic status is correlated to
life style factors such as obesity and smoking, and
although only an approximation, our results were not
altered by adjustment for socioeconomic status.
Conclusions
In this large cohort of more than 4.6 million men and
women of ages 20–89, we found that diabetes and hyper-
tension were associated with an increased risk of incident
all-site cancer across sex, age and calendar year with par-
ticularly high relative risks in the youngest age groups.
Diabetes was associated with the highest cancer risk in
both sexes, followed by hypertension, whereas hyperchol-
esterolemia treated with statins was not associated with
cancer risk. Our results stress the importance of prophy-
lactic awareness among patients with diabetes and/or
hypertension, not only because of increased cardiovascular
risk, but also because of increased associated cancer risk.
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